The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Celgene
Stock and Other Ownership Interests - Celgene
Factors influencing first-line therapy of acute myeloid leukemia (AML) patients (pts) in the Connect MDS/AML Disease Registry.
 
Christopher R. Cogle
Honoraria - Celgene
Patents, Royalties, Other Intellectual Property - DNAtrix
Expert Testimony - IMS Health
 
Daniel Aaron Pollyea
Consulting or Advisory Role - Abbvie; Agios; argenx; Celgene; Celyad; Curis; Pfizer; SERVIER
Research Funding - Agios (Inst); Pfizer (Inst)
 
Mehrdad Abedi
Consulting or Advisory Role - Celgene; Kite, a Gilead company; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Seagen; Takeda
 
Michael A. Thompson
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - AIM Specialty Health; Celgene; GlaxoSmithKline; Takeda; VIA Oncology
Patents, Royalties, Other Intellectual Property - UpToDate, Peer Review for Plasma Cell Dyscrasias (Editor: Robert Kyle)
Travel, Accommodations, Expenses - GlaxoSmithKline; Takeda
Other Relationship - Doximity
 
Gail J. Roboz
Consulting or Advisory Role - Abbvie; Amgen; Amphivena; argenx; Array BioPharma; Astex Pharmaceuticals; Bayer; Celgene; Cellectis; Celltrion; Clovis Oncology; CTI; Eisai; Genentech/Roche; Genoptix; Immune Pharmaceuticals; Janssen; Jazz Pharmaceuticals; MedImmune; Novartis; Orsenix; Pfizer; Sandoz; Sunesis Pharmaceuticals
Research Funding - Abbvie (Inst); Agios (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Cellectis (Inst); CTI (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); MEI Pharma (Inst); Moffitt (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; Amphivena; Array BioPharma; Astex Pharmaceuticals; Bayer; Celgene; Celltrion; Clovis Oncology; Eisai; Janssen; Jazz Pharmaceuticals; Novartis; Pfizer; Roche/Genentech; Sandoz; Sunesis Pharmaceuticals
 
Chrystal Ursula Louis
Employment - Celgene
Stock and Other Ownership Interests - Celgene
Patents, Royalties, Other Intellectual Property - Cell Medica
 
E. Dawn Flick
No Relationships to Disclose
 
Melissa Nifenecker
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Pavel Kiselev
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Arlene S. Swern
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Harry Paul Erba
Consulting or Advisory Role - Agios; Celgene; Daiichi Sankyo; Genoptix; GlycoMimetics; ImmunoGen; Incyte; Macrogenics; Novartis; Ono Pharmaceutical; Pfizer; Seagen
Speakers' Bureau - Agios; Celgene; Incyte; Jazz Pharmaceuticals; Novartis
Research Funding - Agios (Inst); Amgen (Inst); Astellas Pharma (Inst); Celator (Inst); Daiichi Sankyo (Inst); ImmunoGen (Inst); Janssen (Inst); Juno Therapeutics (Inst); Millennium (Inst)
Other Relationship - Celgene; GlycoMimetics